Companies: 10,795·Total market cap: $144.5T
Jade Biosciences, Inc.

Jade Biosciences, Inc.

JBIONASDAQHealthcare● Active
$15.17
+$0.19(+1.26%)
Market Cap$494900942
P/E Ratio
52W High$28
52W Low$6.565
Overview

Jade Biosciences, Inc. (JBIO) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001798749 · JBIO · NASDAQ · as of Jun 10, 2026

Filing snapshot

485
Total Filings
SCHEDULE 13D/A
Latest Form
2026-06-09
Most Recent
2025
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001798749 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-06
Fiscal Year End
Mar 6, 2026
Accession No.
0001193125-26-096550
Primary Document
ck0001798749-20251231.htm
Source: data.sec.gov · CIK 0001798749 · Accession 0001193125-26-096550

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
8-K
2026-06-04Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-06-09
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-06-05
View
8-KCurrent Report
8-K
2026-06-04
View
424B5424B5
424B5
2026-06-04
View
424B5424B5
424B5
2026-06-03
View
8-KCurrent Report
8-K
2026-06-01
View
EFFECTEFFECT
EFFECT
2026-05-15
View
EFFECTEFFECT
EFFECT
2026-05-15
View
424B3424B3
424B3
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
S-8Employee Stock Plan Registration
S-8
2026-05-07
View
S-3Shelf Registration
S-3
2026-05-07
View
S-3Shelf Registration
S-3
2026-05-07
View
424B3424B3
424B3
2026-05-07
View
424B3424B3
424B3
2026-05-07
View
Showing 1–15 of 255 filingsForm 4 / 144 hidden· 485 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001798749  |  Exchange: NASDAQ · Healthcare

Jade Biosciences, Inc. (NASDAQ: JBIO) has submitted 485 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2025. As a Healthcare sector company with CIK 0001798749, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Jade Biosciences, Inc.'s most comprehensive regulatory disclosure. The most recent Jade Biosciences, Inc. 10-K was filed on 2026-03-06 for fiscal year ending 2026. Historical JBIO 10-K annual reports are available from 2020 through 2026.

Investors researching Jade Biosciences, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10

Frequently Asked Questions

JBIO SEC Filings · 8 questions

Jade Biosciences, Inc. (JBIO) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 485 filings and access original documents at no cost. Jade Biosciences, Inc.'s CIK is 0001798749.

JBIO SEC filingsJade Biosciences, Inc. SEC documentsfind JBIO 10-K